Hedera Dx

Founded in Switzerland in 2021 by Tommi Lehtonen, Damien Lapray and Christian Meisel, Hedera Dx is on a mission to make liquid biopsies a reality in clinical practice globally, in order to help more cancer patients get better therapy options and better outcomes. The Hedera Dx liquid biopsy solution will enable patients coping with cancer to get a minimally invasive blood-based test to find and access better treatment options. The Hedera Prime platform is a registered IVD medical device software and is ISO13485 certified.